Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine - PubMed (original) (raw)
. 2005 Feb 1;65(3):1079-88.
Affiliations
- PMID: 15705910
Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine
Xianzheng Zhou et al. Cancer Res. 2005.
Abstract
A phase I clinical trial with granulocyte-macrophage colony-stimulating factor tumor cell vaccines in patients with metastatic renal cell carcinoma (RCC) showed immune cell infiltration at vaccine sites and delayed-type hypersensitivity (DTH) responses to autologous tumor cells indicative of T-cell immunity. To further characterize RCC T-cell responses and identify relevant RCC-associated antigens, we did a detailed analysis of CD8+ T-cell responses in two vaccinated RCC patients who generated the greatest magnitude of DTH response and also displayed a strong clinical response to vaccination (>90% reduction in metastatic tumor volume). Three separate CD8+ T-cell lines (and subsequent derived clones) derived from patient 24 recognized distinct RCC-associated antigens. One recognized a shared HLA-A*0201-restricted antigen expressed by both renal cancer cells and normal kidney cells. This recognition pattern correlated with a positive DTH test to normal kidney cells despite no evidence of impairment of renal function by the patient's remaining kidney after vaccination. A second line recognized a shared HLA-C7-restricted antigen that was IFN-gamma inducible. A third line recognized a unique HLA-A*0101-restricted RCC antigen derived from a mutated KIAA1440 gene specific to the tumor. In addition, two independent CTL lines and three clones were also generated from patient 26 and they recognized autologous tumor cells restricted through HLA-A*0205, HLA-A/B/C, and HLA-B/C. These results show that paracrine granulocyte-macrophage colony-stimulating factor tumor vaccines may generate a diverse repertoire of tumor-reactive CD8+ T-cell responses and emphasize the importance of polyvalency in the design of cancer immunotherapies.
Similar articles
- Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814 - Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W. Kausche S, et al. Cancer Res. 2006 Dec 1;66(23):11447-54. doi: 10.1158/0008-5472.CAN-06-0998. Cancer Res. 2006. PMID: 17145892 - Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Simons JW, et al. Cancer Res. 1999 Oct 15;59(20):5160-8. Cancer Res. 1999. PMID: 10537292 Clinical Trial. - Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines.
Kawai K, Tani K, Asano S, Akaza H. Kawai K, et al. Mol Urol. 2000 Summer;4(2):43-6. doi: 10.1089/10915360050138567. Mol Urol. 2000. PMID: 12006240 Review. - IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A, Mayer-Mokler A, Reinhardt C. Kirner A, et al. Hum Vaccin Immunother. 2014;10(11):3179-89. doi: 10.4161/21645515.2014.983857. Hum Vaccin Immunother. 2014. PMID: 25625928 Free PMC article. Review.
Cited by
- Standardization of esophageal adenocarcinoma in vitro model and its applicability for model drug testing.
Tratnjek L, Sibinovska N, Kralj S, Makovec D, Kristan K, Kreft ME. Tratnjek L, et al. Sci Rep. 2021 Mar 23;11(1):6664. doi: 10.1038/s41598-021-85530-w. Sci Rep. 2021. PMID: 33758229 Free PMC article. - Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung SI. Pan RY, et al. J Immunol Res. 2018 Dec 19;2018:4325874. doi: 10.1155/2018/4325874. eCollection 2018. J Immunol Res. 2018. PMID: 30662919 Free PMC article. Review. - Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Nat Rev Cancer. 2017. PMID: 28233802 Free PMC article. Review. - Cancer immunotherapy targeting neoantigens.
Lu YC, Robbins PF. Lu YC, et al. Semin Immunol. 2016 Feb;28(1):22-7. doi: 10.1016/j.smim.2015.11.002. Epub 2015 Nov 30. Semin Immunol. 2016. PMID: 26653770 Free PMC article. Review. - IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X. Huang X, et al. PLoS One. 2015 Jul 14;10(7):e0133152. doi: 10.1371/journal.pone.0133152. eCollection 2015. PLoS One. 2015. PMID: 26173023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous